Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria

Michihiro Hide,Hae-Sim Park,Atsuyuki Igarashi,Young-Min Ye,Tae-Bum Kim,Akiko Yagami,Joo-Young Roh,Jae-Hyun Lee,Yuko Chinuki,Sang Woong Youn,Soo-Keol Lee,Naoko Inomata,Jeong-Hee Choi,Atsushi Fukunaga,Junyi Wang,Soichiro Matsushima,Steve Greenberg,Sam Khalil

Journal of Dermatological Science（2017）

引用 51|浏览41

暂无评分

摘要

•The first phase III trial of omalizumab for CSU in an East Asian population was performed.•Omalizumab was efficacious in H1 antihistamine-refractory patients with CSU.•Omalizumab was well tolerated in Japanese and Korean CSU patients.•Findings were consistent with results of previous global studies of omalizumab.

查看译文

关键词

AE,ANCOVA,BMI,BOCF,CIU,CSU,DLQI,EAACI,EDF,FAS,GA2LEN,H1AH,IRT,JDA,LOCF,LS,LTRA,MID,MMRM,PPS,QoL,SAE,SAF,SE,UAS,WAO

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要